Alpha-1 antitrypsin inhibits SARS-CoV-2 infection
Wettstein, L.; Conzelmann, C.; Mueller, J. A.; Weil, T.; Gross, R.; Hirschenberger, M.; Seidel, A.; Klute, S.; Prelli-Bozzo, c.; Zech, F.; Preising, N.; Fois, G.; Lochbaum, R.; Knaff, P.; Mailaender, V.; Staendker, L.; Thal, D.; Schumann, C.; Stenger, S.; Sparrer, K.; Kleger, A.; Lochnit, G.; Kirchhoff, F.; Frick, M.; Muench, J.
Show abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). To identify factors of the respiratory tract that suppress SARS-CoV-2, we screened a peptide/protein library derived from bronchoalveolar lavage, and identified 1-antitrypsin (1-AT) as specific inhibitor of SARS-CoV-2. 1-AT targets the viral spike protein and blocks SARS-CoV-2 infection of human airway epithelium at physiological concentrations. Our findings show that endogenous 1-AT restricts SARS-CoV-2 and repurposes 1-AT-based drugs for COVID-19 therapy.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
- Targeting the latent human cytomegalovirus reservoir with virus specific nanobodies 95%
- De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report 95%
Similar papers in this journal
Similar papers in this journal
- The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells 95%
- Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains 94%
- Enterovirus A71 adaptation to heparan sulfate comes with capsid stability tradeoff 94%
Similar papers in this journal
- Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection 95%
- TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron infection 94%
- Proinflammatory responses in SARS-CoV-2 infected and soluble spike glycoprotein S1 subunit activated human macrophages 94%
Similar papers in this journal
- SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion 97%
- A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures 95%
- SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.